Several members of the GIM faculty and research staff have published a systematic review and meta-analysis of pharmacotherapies for the treatment of alcohol use disorder in JAMA. The review included a rigorous analysis of data from 118 clinical trials involving 20,976 participants. Key results indicated that both acamprosate and oral naltrexone at 50mg/day significantly reduce the likelihood of a person returning to any drinking. The study sheds light on the effectiveness of these treatments and can inform future clinical guidelines, potentially improving the quality of life for millions affected by alcohol use disorder. The work was done through GIM’s Evidence-based Practice Center in collaboration with the RTI-UNC Evidence-based Practice Center. GIM Division Director Daniel Jonas, MD, MPH (top left in photo) served as senior author; Sean Riley, MSc, MA (top middle) provided research support and conducted the meta-analyses; Christiane Voisin, MSLS (top right) served as research librarian; and Cory Coffey, PharmD, BCACP, BCPP (bottom left) and Kaitlin Kuznacic, PharmD (bottom middle) offered research support as GIM pharmacists.
